aspirin has been researched along with Adverse Effects, Long Term in 8 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Bleeding (n = 100) and quality of life (n = 90) were assessed using validated questionnaires: Warfarin and Aspirin Bleeding assessment tool and Pediatric Quality of Life Inventory, respectively." | 4.02 | Long-term outcomes of warfarin versus aspirin after Fontan surgery. ( Attard, C; Briody, J; Cordina, R; d'Udekem, Y; Hassan, EB; Ignjatovic, V; Mackay, MT; Monagle, PT; Rice, K; Simm, P, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Taha, A | 1 |
| Nielsen, SJ | 1 |
| Bergfeldt, L | 1 |
| Ahlsson, A | 1 |
| Friberg, L | 1 |
| Björck, S | 1 |
| Franzén, S | 1 |
| Jeppsson, A | 1 |
| Attard, C | 1 |
| Monagle, PT | 1 |
| d'Udekem, Y | 1 |
| Mackay, MT | 1 |
| Briody, J | 1 |
| Cordina, R | 1 |
| Hassan, EB | 1 |
| Simm, P | 1 |
| Rice, K | 1 |
| Ignjatovic, V | 1 |
| Zwart, B | 1 |
| Ten Berg, JM | 2 |
| Godschalk, TC | 1 |
| Gimbel, ME | 1 |
| Nolet, WW | 1 |
| van Kessel, DJ | 1 |
| Amoroso, G | 1 |
| Dewilde, WJ | 1 |
| Wykrzykowska, JJ | 1 |
| Janssen, PW | 1 |
| Bergmeijer, TO | 1 |
| Kelder, JC | 1 |
| Heestermans, T | 1 |
| Ye, S | 1 |
| Lee, M | 1 |
| Lee, D | 1 |
| Ha, EH | 1 |
| Chun, EM | 1 |
| Stadler, RR | 1 |
| Kindler, R | 1 |
| Holzmann, D | 1 |
| Soyka, MB | 1 |
| Grodzinsky, A | 1 |
| Arnold, SV | 1 |
| Wang, TY | 1 |
| Sharma, P | 1 |
| Gosch, K | 1 |
| Jones, PG | 1 |
| Bhatt, DL | 1 |
| Steg, PG | 1 |
| McGuire, DK | 1 |
| Cohen, DJ | 1 |
| Spertus, JA | 1 |
| Chhatriwalla, AK | 1 |
| Lind, M | 1 |
| Graham, G | 1 |
| Kosiborod, M | 1 |
| Goodman, SG | 1 |
| Nicolau, JC | 1 |
| Requena, G | 1 |
| Maguire, A | 1 |
| Blankenberg, S | 1 |
| Chen, JY | 1 |
| Granger, CB | 1 |
| Grieve, R | 1 |
| Pocock, SJ | 1 |
| Simon, T | 1 |
| Yasuda, S | 1 |
| Vega, AM | 1 |
| Brieger, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG[NCT04045665] | Phase 3 | 3,200 participants (Anticipated) | Interventional | 2019-12-13 | Recruiting | ||
| TIGRIS: Long-Term rIsk, Clinical manaGement and Healthcare Resource Utilization of Stable Coronary Artery dISease in Post Myocardial Infarction Patients[NCT01866904] | 9,284 participants (Actual) | Observational | 2013-06-19 | Terminated (stopped due to Study was terminated in order to secure the data quality of the study in terms of follow-up rates and data completeness.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for aspirin and Adverse Effects, Long Term
| Article | Year |
|---|---|
New-Onset Atrial Fibrillation After Coronary Artery Bypass Grafting and Long-Term Outcome: A Population-Based Nationwide Study From the SWEDEHEART Registry.
Topics: Aged; Aspirin; Atrial Fibrillation; Coronary Artery Bypass; Coronary Artery Disease; Factor Xa Inhib | 2021 |
7 other studies available for aspirin and Adverse Effects, Long Term
| Article | Year |
|---|---|
Long-term outcomes of warfarin versus aspirin after Fontan surgery.
Topics: Anticoagulants; Aspirin; Australia; Bone Density; Chemoprevention; Child; Cohort Studies; Female; Fo | 2021 |
Antiplatelet therapy: New score for predicting bleeding risk after DAPT.
Topics: Aspirin; Clinical Trials as Topic; Coronary Restenosis; Hemorrhage; Humans; Long Term Adverse Effect | 2017 |
A clinical risk score to identify patients at high risk of very late stent thrombosis.
Topics: Aspirin; Case-Control Studies; Female; Hemorrhage; Humans; Long Term Adverse Effects; Male; Middle A | 2018 |
Association of Long-term Use of Low-Dose Aspirin as Chemoprevention With Risk of Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Dis | 2019 |
The long-term fate of epistaxis patients with exposure to antithrombotic medication.
Topics: Adult; Aspirin; Cohort Studies; Epistaxis; Female; Fibrinolytic Agents; Humans; Long Term Adverse Ef | 2016 |
Bleeding risk following percutaneous coronary intervention in patients with diabetes prescribed dual anti-platelet therapy.
Topics: Aged; Aspirin; Comorbidity; Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; D | 2016 |
Longer-term oral antiplatelet use in stable post-myocardial infarction patients: Insights from the long Term rIsk, clinical manaGement and healthcare Resource utilization of stable coronary artery dISease (TIGRIS) observational study.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Femal | 2017 |